Tags

Type your tag names separated by a space and hit enter

GnRH antagonist-induced inhibition of the premature LH surge increases pregnancy rates in IUI-stimulated cycles. A prospective randomized trial.
Hum Reprod. 2007 Jan; 22(1):101-8.HR

Abstract

BACKGROUND

Our prospective randomized controlled trial was designed to assess whether the use of GnRH antagonists can improve the success rate of controlled ovarian stimulation (COS)/intrauterine insemination (IUI) treatments, via inhibition of the premature LH rise.

METHODS

A total of 104 patients were randomly divided, using a randomization list, into two groups: in group A (n = 52), recombinant FSH (rFSH) was given with GnRH antagonist Cetrorelix, and in group B (n = 52), the patients received rFSH alone in a manner similar to that of group A. The primary outcome measure was clinical pregnancy rate per couple.

RESULTS

The pregnancy rate per patient was 53.8% in group A and 30.8% in group B (P = 0.017). The rate of premature LH surge was 7% in group A and 35% in group B (P < 0.0001). A premature luteinization was observed in two cycles of 144 in group A (1.4%) and in 16 cycles of 154 in group B (10.4%) (P = 0.001). The mean values of LH and progesterone were significantly lower in patients receiving GnRH antagonist than in those who did not (3.3 +/- 3.3 mIU/ml in group A versus 9.9 +/- 7.9 mIU/ml in group B, P < 0.0001, for LH; 1.3 +/- 1.1 ng/ml versus 2.1 +/- 1.9 ng/ml for group A and B, respectively, P < 0.0001, for progesterone).

CONCLUSION

The use of GnRH antagonist in COS/IUI cycles improves pregnancy rate, preventing the premature LH rise and luteinization.

Authors+Show Affiliations

ANDROS Day Surgery, Reproductive Medicine Unit, Palermo, Italy. allegra@centroandros.itNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

17032732

Citation

Allegra, A, et al. "GnRH Antagonist-induced Inhibition of the Premature LH Surge Increases Pregnancy Rates in IUI-stimulated Cycles. a Prospective Randomized Trial." Human Reproduction (Oxford, England), vol. 22, no. 1, 2007, pp. 101-8.
Allegra A, Marino A, Coffaro F, et al. GnRH antagonist-induced inhibition of the premature LH surge increases pregnancy rates in IUI-stimulated cycles. A prospective randomized trial. Hum Reprod. 2007;22(1):101-8.
Allegra, A., Marino, A., Coffaro, F., Scaglione, P., Sammartano, F., Rizza, G., & Volpes, A. (2007). GnRH antagonist-induced inhibition of the premature LH surge increases pregnancy rates in IUI-stimulated cycles. A prospective randomized trial. Human Reproduction (Oxford, England), 22(1), 101-8.
Allegra A, et al. GnRH Antagonist-induced Inhibition of the Premature LH Surge Increases Pregnancy Rates in IUI-stimulated Cycles. a Prospective Randomized Trial. Hum Reprod. 2007;22(1):101-8. PubMed PMID: 17032732.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - GnRH antagonist-induced inhibition of the premature LH surge increases pregnancy rates in IUI-stimulated cycles. A prospective randomized trial. AU - Allegra,A, AU - Marino,A, AU - Coffaro,F, AU - Scaglione,P, AU - Sammartano,F, AU - Rizza,G, AU - Volpes,A, Y1 - 2006/10/10/ PY - 2006/10/13/pubmed PY - 2007/3/17/medline PY - 2006/10/13/entrez SP - 101 EP - 8 JF - Human reproduction (Oxford, England) JO - Hum. Reprod. VL - 22 IS - 1 N2 - BACKGROUND: Our prospective randomized controlled trial was designed to assess whether the use of GnRH antagonists can improve the success rate of controlled ovarian stimulation (COS)/intrauterine insemination (IUI) treatments, via inhibition of the premature LH rise. METHODS: A total of 104 patients were randomly divided, using a randomization list, into two groups: in group A (n = 52), recombinant FSH (rFSH) was given with GnRH antagonist Cetrorelix, and in group B (n = 52), the patients received rFSH alone in a manner similar to that of group A. The primary outcome measure was clinical pregnancy rate per couple. RESULTS: The pregnancy rate per patient was 53.8% in group A and 30.8% in group B (P = 0.017). The rate of premature LH surge was 7% in group A and 35% in group B (P < 0.0001). A premature luteinization was observed in two cycles of 144 in group A (1.4%) and in 16 cycles of 154 in group B (10.4%) (P = 0.001). The mean values of LH and progesterone were significantly lower in patients receiving GnRH antagonist than in those who did not (3.3 +/- 3.3 mIU/ml in group A versus 9.9 +/- 7.9 mIU/ml in group B, P < 0.0001, for LH; 1.3 +/- 1.1 ng/ml versus 2.1 +/- 1.9 ng/ml for group A and B, respectively, P < 0.0001, for progesterone). CONCLUSION: The use of GnRH antagonist in COS/IUI cycles improves pregnancy rate, preventing the premature LH rise and luteinization. SN - 0268-1161 UR - https://www.unboundmedicine.com/medline/citation/17032732/GnRH_antagonist_induced_inhibition_of_the_premature_LH_surge_increases_pregnancy_rates_in_IUI_stimulated_cycles__A_prospective_randomized_trial_ L2 - https://academic.oup.com/humrep/article-lookup/doi/10.1093/humrep/del337 DB - PRIME DP - Unbound Medicine ER -